InflaRx files Form 6-K with 9M 2025 financials

Accepted by SEC EDGAR 11/10/2025 - 07:20 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

InflaRx N.V. submitted a Form 6-K as a foreign private issuer, furnishing unaudited condensed consolidated financial statements as of and for the nine months ended September 30, 2025, together with management’s discussion and analysis of financial condition and results of operations.

The company states these exhibits are incorporated by reference into its existing Form S-8 registration statements and its Form F-3 shelf registration, making the new financial information part of those effective securities registration documents.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does InflaRx (IFRX) report in this November 2025 Form 6-K?

InflaRx reports unaudited condensed consolidated financial statements and related management discussion for the nine months ended September 30, 2025. These materials update investors on financial condition and results of operations and are furnished as exhibits to the Form 6-K.

Which financial period do InflaRx (IFRX) statements in this Form 6-K cover?

The statements cover InflaRx’s unaudited condensed consolidated results as of and for the nine months ended September 30, 2025. This period gives investors a year-to-date view of the company’s financial position and operations performance in 2025.

How is this InflaRx (IFRX) Form 6-K linked to existing registration statements?

The exhibits to this Form 6-K are incorporated by reference into InflaRx’s Form S-8 registration statements and its Form F-3 registration statement. That means the furnished financial statements and MD&A legally become part of those registration documents from the submission date.

What specific exhibits are included with this InflaRx (IFRX) Form 6-K?

The Form 6-K includes Exhibit 99.1, InflaRx’s unaudited condensed consolidated financial statements for the nine months ended September 30, 2025, and Exhibit 99.2, management’s discussion and analysis of financial condition and results of operations for the same period.

Who signed the InflaRx (IFRX) Form 6-K and in what capacity?

The Form 6-K was signed on behalf of InflaRx N.V. by Niels Riedemann, who is identified as the company’s Chief Executive Officer. His signature confirms the company has duly caused the report to be submitted under the Exchange Act.

Where is InflaRx (IFRX) headquartered according to this Form 6-K?

InflaRx N.V. lists its principal executive office at Winzerlaer Str. 2, 07745 Jena, Germany. This address identifies the company’s main operational and administrative base as presented in the Form 6-K header information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-38283

InflaRx N.V.
(Translation of registrant's name into English)

Winzerlaer Str. 2
07745 Jena, Germany
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

EXPLANATORY NOTE

Exhibits 99.1 and 99.2 to this report on Form 6-K (the “Report”) shall be deemed to be incorporated by reference into (i) the registration statements on Form S-8 (File No. 333-221656 and 333-240185) and (ii) the registration statement on Form F-3 (File No. 333-273058) of InflaRx N.V. and to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit No.	Description
99.1	InflaRx N.V. Unaudited Condensed Consolidated Financial Statements as of and for the Nine Months Ended September 30, 2025
99.2	InflaRx N.V. Management’s Discussion and Analysis of Financial Condition and Results of Operations

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	INFLARX N.V.
Date: November 10, 2025	By:	/s/ Niels Riedemann
	Name:	Niels Riedemann
	Title:	Chief Executive Officer